

Thyroid Eye Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/T48977548808EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: T48977548808EN

Abstracts

The 7 major thyroid eye disease markets reached a value of US\$ 2,122.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 4,139.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.26% during 2024-2034.

The thyroid eye disease market has been comprehensively analyzed in IMARC's new report titled "Thyroid Eye Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thyroid eye disease, also known as Graves' ophthalmopathy or Graves' orbitopathy, is an autoimmune condition characterized by inflammation as well as swelling of the tissues around the eyes. It is primarily associated with an overactive thyroid gland (hyperthyroidism) caused by Graves' disease. However, the ailment can also occur in individuals suffering from normal thyroid function or even those with an underactive thyroid (hypothyroidism). It is characterized by a range of symptoms affecting the eyes and surrounding tissues, such as eye bulging (proptosis), eye pain, double vision (diplopia), dry eyes, redness and swelling of the eyelids, difficulty closing the eyes completely, changes in vision, etc. Diagnosing thyroid eye disease involves a comprehensive evaluation that typically consists of a detailed medical history, physical examination, assessment of eye symptoms, and specific diagnostic tests. Various clinical features, including eye bulging, eyelid retraction, double vision, eye redness, etc., are evaluated. Numerous imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), may be used to visualize the orbital structures and detect inflammation or tissue changes. Additionally, several thyroid function tests, including measurement of thyroid hormone levels and thyroid antibody testing, help to support the disease diagnosis.

The rising cases of autoimmune disorders in which the immune system mistakenly

targets the thyroid-stimulating hormone receptor on cells within the orbital tissues surrounding the eyes are primarily driving the thyroid eye disease market. In addition to this, the increasing prevalence of several associated risk factors, including hyperthyroidism, genetic predisposition, smoking, exposure to radiation or trauma, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of artificial tears and lubricating eye drops to alleviate dryness and provide temporary relief from discomfort is further augmenting the market growth. Additionally, the inflating utilization of orbital decompression surgery in cases where there is severe eye bulging or compression of the optic nerve is acting as another significant growth-inducing factor. This procedure involves removing some of the bone and fat around the eye socket to create more space for the swollen tissues. Furthermore, the escalating demand for strabismus surgery to help realign the eye muscles, restore normal vision, and reduce double vision is also bolstering the market growth. Besides this, the emerging popularity of orbital electromyography (EMG), since it aids in assessing muscle involvement and detecting muscle inflammation or fibrosis, is expected to drive the thyroid eye disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the thyroid eye disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thyroid eye disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thyroid eye disease market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the thyroid eye disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the thyroid eye disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current thyroid eye disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the thyroid eye disease market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the thyroid eye disease market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the thyroid eye disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of thyroid eye disease across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of thyroid eye disease by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of thyroid eye disease by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with thyroid eye disease across the seven major markets?

What is the size of the thyroid eye disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of thyroid eye disease?

What will be the growth rate of patients across the seven major markets?

Thyroid Eye Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for thyroid eye disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thyroid eye disease market?

What are the key regulatory events related to the thyroid eye disease market?

What is the structure of clinical trial landscape by status related to the thyroid eye disease market?

What is the structure of clinical trial landscape by phase related to the thyroid eye disease market?

What is the structure of clinical trial landscape by route of administration related to the thyroid eye disease market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 THYROID EYE DISEASE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 THYROID EYE DISEASE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 THYROID EYE DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 THYROID EYE DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 THYROID EYE DISEASE - UNMET NEEDS

10 THYROID EYE DISEASE - KEY ENDPOINTS OF TREATMENT

11 THYROID EYE DISEASE - MARKETED PRODUCTS

- 11.1 List of Thyroid Eye Disease Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Tepezza (Teprotumumab) - Horizon Therapeutics
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 THYROID EYE DISEASE - PIPELINE DRUGS

12.1 List of Thyroid Eye Disease Pipeline Drugs Across the Top 7 Markets

12.1.1 VRDN 001 - Viridian Therapeutics

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 VB 421 - Pierre Fabre/ACELYRIN

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 Batoclimab - HanAll Biopharma/Harbour BioMed/Immunovant

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 Linsitinib - Sling Therapeutics

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. THYROID EYE DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. THYROID EYE DISEASE – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 THYROID EYE DISEASE - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Thyroid Eye Disease - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Thyroid Eye Disease - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Thyroid Eye Disease - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Thyroid Eye Disease - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Thyroid Eye Disease - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Thyroid Eye Disease - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Thyroid Eye Disease - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Thyroid Eye Disease - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Thyroid Eye Disease - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Thyroid Eye Disease - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Thyroid Eye Disease - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Thyroid Eye Disease - Market Size

15.6.1.1 Market Size (2018-2023)

- 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Thyroid Eye Disease - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Thyroid Eye Disease - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Thyroid Eye Disease - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Thyroid Eye Disease - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Thyroid Eye Disease - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Thyroid Eye Disease - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Thyroid Eye Disease - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Thyroid Eye Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Thyroid Eye Disease - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Thyroid Eye Disease - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Thyroid Eye Disease - Access and Reimbursement Overview

16 THYROID EYE DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 THYROID EYE DISEASE MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 THYROID EYE DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Thyroid Eye Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/T48977548808EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T48977548808EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

